Open Access

Erratum to: Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

  • Bi-Yun Wang1, 2,
  • Jian Zhang1, 2,
  • Jia-Lei Wang1, 2,
  • Si Sun1, 2,
  • Zhong-Hua Wang1, 2,
  • Lei-Ping Wang1, 2,
  • Qun-Ling Zhang1, 2,
  • Fang-Fang Lv1, 2,
  • En-Ying Cao1, 2,
  • Zhi-Min Shao2, 3,
  • Stefano Fais4Email author and
  • Xi-Chun Hu1, 2Email author
Contributed equally
Journal of Experimental & Clinical Cancer Research201534:109

https://doi.org/10.1186/s13046-015-0220-z

Received: 1 September 2015

Accepted: 9 September 2015

Published: 1 October 2015

Unfortunately, the original version of this article [1] contained an error. The original article was published containing two incorrect sentences.

This sentence appeared in the abstract as follows “A significant difference was observed between patients who had taken PPI and who not with ORR (46.9 vs. 67.7 %, p = 0.049) and median TTP (9.7 months vs. 8.7 months, p = 0.045).” This should have read as “A significant difference was observed between patients who had taken PPI and who not with ORR (67.7 vs. 46.9 %, p = 0.049) and median TTP (9.7 months vs. 8.7 months, p = 0.045).”

The following sentence which appeared in the main text was also incorrect. In the original article it read as “As planned, we compared the pool of patients receiving PPI to those treated exclusively with chemotherapy and the statistical analysis showed a significant difference in term of ORR between patients who received PPI, as compared to those treated with chemotherapy alone (46.9 vs. 67.7 %, p = 0.049).” However this should have read as “As planned, we compared the pool of patients receiving PPI to those treated exclusively with chemotherapy and the statistical analysis showed a significant difference in term of ORR between patients who received PPI, as compared to those treated with chemotherapy alone (67.7 vs. 46.9 %, p = 0.049).”

Both sentences have now been corrected in the original article. The author apologizes for any inconvenience caused.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Medical Oncology, Fudan University Shanghai Cancer Center
(2)
Department of Oncology, Shanghai Medical College, Fudan University
(3)
Department of Breast Surgery, Fudan University Shanghai Cancer Center
(4)
Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health

Reference

  1. J Exp Clin Cancer Res. 2015; 34:85. doi:10.1186/s13046-015-0194-x.

Copyright

© Wang et al. 2015

Advertisement